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license (http://creativeease. We found improvements in cognitive, neuropsychiatric, and physical measures in the partici-
pants who adhered to the protocol. Epidemiological studies in healthy elderly suggest that exercise
preserves cognitive and physical abilities to a higher extent in APOE ε4 carriers.
Methods: In this post hoc subgroup analysis study, we investigated whether the beneficial effect of
an exercise intervention in patients with mild AD was dependent on the patients’ APOE genotype.
Results: We found that patients who were APOE ε4 carriers benefitted more from the exercise inter-
vention by preservation of cognitive performance and improvement in physical measures.
Discussion: This exploratory study establishes a possible connection between the beneficial effects
of exercise in AD and the patients’ APOE genotype. These findings, if validated, could greatly impact
the clinical management of patients with AD and those at risk for developing AD.
 2019 The Author. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Cognitive decline in late life and dementia are associated
with decreases in activities of daily living, quality of life, and
increased mortality. There are an estimated 46.8 million
people living with dementia worldwide [1], and with an
aging population, dementia and Alzheimer’s disease (AD)re no conflicts of interest.
ntributed equally to the manuscript.
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/j.trci.2019.02.007
he Author. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).constitute a growing health and economic burden [1,2].
Several genetic, environmental, and clinical risk factors for
developing AD have been identified. The presence of the
apolipoprotein-E (APOE) ε4 allele is the most important ge-
netic risk factor, whereas physical inactivity is a major life-
style risk factor for the development of AD [3].
The ε4 allele of the APOE gene located on chromosome
19 is associated with higher risk of developing AD and at an
earlier age, whereas the ε2 allele has a protective effect
against AD, and the ε3 allele is considered neutral [4].
The neuropathological hallmarks ofADare intracellular neuro-
fibrillary tangles and extracellular plaques composed of tau andimer’s Association. This is an open access article under the CC BY-NC-ND
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logical findings include increased inflammation and oxidative
stress [6,7]. It has been suggested that APOE ε4 genotype can
lead to AD pathogenesis by several pathways: (1) damage of
the vascular system in the brain; (2) initiation or acceleration
of A-beta accumulation, aggregation, and deposition in the
brain; (3) impaired cholesterol transport; and (4) increased
neuroinflammation [4].
In animal and human studies, exercise has shown a neu-
roprotective effect, notably in the hippocampus and the
dentate gyrus, both areas showing pathological changes in
AD [8–11]. Observational studies in healthy elderly
persons show that higher levels of physical activity are
associated with lower risk of cognitive decline, better
cognitive performance, and preservation of hippocampal
volume and that the effect was stronger in APOE ε4
carriers when compared to noncarriers [12–14].
Furthermore, higher levels of physical activity have been
associated with faster reaction time in APOE ε4 carriers
compared to noncarriers [15]. In subjects with MCI, 1 study
investigated the effect of APOE genotype on physical func-
tion and found that walking speed was reduced in the APOE
ε4 carriers, compared to noncarriers [16]. Despite evidence
from observational studies in healthy elderly and MCI sub-
jects of associations between physical inactivity, cognitive
decline, and APOE ε4 carrier status, there is a paucity of
knowledge of these associations in subjects with AD de-
mentia. Similarly, in exercise intervention studies, positive
effect of APOE ε4 carrier status on cognition has been
found in healthy elderly subjects [17,18], but to the best
of our knowledge, this effect has not been evaluated in
patients with AD.
Because the search for pharmacological treatments to
slow down or reverse AD has not proven successful so far
[19], researchers have turned their attention toward nonphar-
macological approaches, including exercise, to try to slow
the cognitive decline [20,21]. Our group has previously
investigated the effect of exercise in patients with mild AD
in the “Preserving Cognition, Quality of Life, Physical
Health and Functional Ability in Alzheimer’s disease: The
Effect of Physical Exercise (ADEX) study” [22]. In that
study, for subjects who adhered to the protocol, we found
a significant improvement in cognitive performance
measured by the Symbol Digit Modalities Test (SDMT),
neuropsychiatric symptoms [22], as well as in physical
function [23].
Results of all cognitive tests (SDMT, ADAS-Cog, Stroop
Color and Word test, verbal fluency, and MMSE) have been
published [22]; we found a significant effect of exercise on
our primary outcome measure, SDMT, but no effect of the
exercise intervention was detected on the other cognitive
tests. SDMT was chosen as primary outcome because this
test is sensitive to very early changes in aspects of executive
function (mental speed and attention) in AD [24]. Executive
function is considered to be particularly sensitive to the
effect of physical exercise [25,26], which recently wascorroborated in two trials of moderate- to high-intensity ex-
ercise in sedentary older adults [27] and patients with MCI
[28] where executive function and performance on SDMT
was improved by exercise.
In this post hoc subgroup analysis of patients with mild
AD from the ADEX study, we aimed to investigate if the
significant improvements in cognitive and physical out-
comes were dependent on the patients’ APOE genotype.2. Materials and methods
2.1. Patient cohort and baseline characteristics
A total of 200 patients from eight memory clinics in
Denmark were randomized to either a control group
(n5 93) or an intervention group (n5 107), and 190 patients
completed follow-up [29]. The inclusion/exclusion criteria
have been described previously in the study by Hoffmann
et al. [30]. Briefly, the patients were diagnosed with AD
according to the NINCDS-ADRDA criteria [29] before
enrollment in the trial, were between 50 and 90 years of
age, and had a MMSE score 20.
Patient baseline characteristics have been summarized in
Table 1. All patients gave blood samples before and after the
intervention. The patients’ APOE genotype was not known
at the time of the exercise intervention because APOE
genotyping was not part of the routine diagnostic procedure
and was only analyzed after the end of the trial.
The study was approved by the ethical committee of the
Capital Region of Denmark (H-3-2011-128) and the Danish
Data protection agency (Capital Region of Denmark,
30-0718). All patients gave informed consent before
enrollment (ClinicalTrials.gov registration number:
NCT01681602).2.2. Exercise intervention
The physical exercise intervention was supervised aero-
bic exercise at moderate-to-high intensity (70–80% of
maximal heart rate [HR] measured by pulse watches) 1
hour, three times weekly for 16 weeks in groups of two to
five participants. The exercise protocol has been described
in detail in the study by Sobol et al. [31] and consisted of
a short warm-up session followed by aerobic exercise on
treadmill, stationary bike, and cross-trainer.2.3. APOE genotype
DNA was isolated with Promega Maxwell DNA
purification kits (Promega, Madison, WI), according to the
manufacturer’s protocol from 250 mL of buffy coat from
6 mL EDTA vials. APOE genotyping for the ε2, ε3, and ε4
alleles was performed with a TaqMan qPCR assay as
described by Koch et al. [32].
Table 1
Baseline characteristics of the study cohort
Controls Exercise
APOE ε4 noncarriers APOE ε4 carriers P value APOE ε4 noncarriers APOE ε4 carriers P value
n 21 72 (27 homozygotes) 34 72 (27 homozygotes)
Gender 0.45* 0.23*
Males, n (%) 11 (52.4) 41 (56.9) 17 (50) 43 (59.7)
Females, n (%) 10 (47.6) 31 (43.1) 17 (50) 29 (40.3)
Age, yearsy 68.0 (8.8) 72.5 (6.5) 0.01z 67.9 (9.1) 70.8 (6.4) 0.06z
MMSEy 25.0 (3.6) 23.9 (3.9) 0.27z 24.4 (3.5) 23.6 (3.3) 0.26z
Education, yearsy 11.5 (2.9) 11.9 (2.7) 0.55z 12.0 (2.9) 11.9 (2.6) 0.83z
P values are APOE ε4 carriers versus APOE ε4 noncarriers. Bold value denotes statistical significance P , 0.05.
*Chi-squared test.
yGiven as mean 6 (standard deviation).
zIndependent t-test.
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We have previously published the results of our exercise
intervention on cognitive [22] and physical [23] outcomes.
We found a significant effect of exercise on neuropsychiatric
symptoms measured by the Neuropsychiatric Inventory
(NPI) in the intention-to-treat group. Patients who reached
the target intervention intensity of 70% of maximum HR
and participated in at least two-thirds of the exercise sessions
(per-protocol group, termed “high exercise group,” n5 66 of
107 patients) improved significantly on NPI as well as on a
cognitive test of attention and mental speed (SDMT). We
therefore chose these two outcomes for analysis in the pre-
sent study to investigate whether the effect was different in
APOE ε4 carriers compared to noncarriers.
2.4.1. Cognitive outcome
SDMT assesses mental speed and attention. Using the
number and symbol key at the top of the test page, partici-
pants were asked to correctly decode several lines of sym-
bols [33]. The total number of correct decodings in 120 s
was used as outcome.
2.4.2. Neuropsychiatric outcome
NPI is a caregiver-rated 12-point questionnaire assessing
12 different behavioral and psychological symptoms com-
mon in AD. The primary caregiver rates each symptom
according to frequency and severity [34].
2.4.3. Physical outcomes
Timed-Up-and-Go test assesses basic mobility by
measuring the time it takes for a person to stand up from a
chair, walk 3 meters, cross a line, turn around, and walk
back to the chair and sit down [35].
Timed 10-meter walk test assesses gait speed on a
10-meter long course [36].
Timed 400-meter walk test assesses walking endurance
measured on a 20-meter long course marked with colored
cones [37].
Dual task performance ismeasuredwith the timed10-meter
walk test combined with counting backward from 50 [36].Maximal oxygen uptake (VO2max): the submaximal test
for estimating maximal oxygen uptake is considered to be
valid for assessing changes in cardiovascular fitness (aerobic
fitness) and is estimated based on the workload and average
HR during the last minute of a 6-minute cycle test, corrected
for age and body weight [38].2.5. Statistical analyses
Baseline characteristics were compared between random-
ization groups and between APOE genotypes with
chi-square tests (categorical characteristics) and t-tests
(continuous characteristics). The effect of the exercise inter-
vention was assessed separately for APOE ε4 carriers and
noncarriers in a linear regression model for each outcome
as intention-to-treat analyses including all patients were
performed and per-protocol analyses where only patients
who reached the target intervention intensity of 70% of
maximum HR and participated in at least two-thirds of the
exercise sessions were included. Possible differential
dropout between the randomization groups was adjusted
for by weighting the available observations by the inverse
of the probability of being in the data, estimated in logistic
regression models including baseline characteristics of the
patients. The analysis was performed with generalized esti-
mating equations to account for the weighting and for
repeated measurements. Analyses were done with SAS
v9.4. A significance level of 5% was used.3. Results
3.1. Patient cohort
Baseline characteristics of the patient cohort are
summarized in Table 1. There was an even distribution
of APOE ε4 carriers versus noncarriers in the control and
intervention groups, with approximately 70% being carriers
of the APOE ε4 allele. We did not find significant differences
in baseline characteristics between the randomization
groups. When analyzed by the patients’ APOE genotype,
the APOE ε4 noncarriers were significantly younger than
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C.S. Jensen et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 5 (2019) 99-106102the APOE ε4 carriers in the control group. There was no
significant difference in gender distribution, MMSE, or
years of education between the APOE ε4 carriers and the
APOE ε4 noncarriers.3.2. Clinical outcomes
Carriers of the APOE ε4 allele who participated in the ex-
ercise arm maintained their performance on SDMT while
APOE ε4 carriers who did not exercise had a decline in per-
formance (Table 2). Exercise did not influence SDMT scores
in the APOE ε4 noncarrier patients. There was a stabilizing
effect of exercise on SDMT inAPOE ε4 carriers compared to
noncarriers, P 5 .0236 (Table 2, Fig. 1).
Similarly, APOE ε4 carriers who exercised had a signifi-
cant and marked improvement in neuropsychiatric symp-
toms as evaluated by NPI compared to the control APOE
ε4 carriers (P 5 .0002), although the effect of exercise on
neuropsychiatric symptoms was absent in the APOE ε4
noncarriers (Table 2, Fig. 1).3.3. Physical outcomes
We found that exercise improved Timed-Up-and-Go test
in the APOE ε4 carriers versus noncarriers, P 5 .0143.
Furthermore, we found significant improvement only in
APOE ε4 carriers for timed 10-meter walk test
(P 5 .0269), and timed 400-meter walk test (P 5 .0425),
and these outcomes did not change significantly in noncar-
riers. Estimated VO2max improved significantly after exer-
cise in both carriers and noncarriers (see Table 2 and Fig. 1).4. Discussion
In this post hoc subgroup analysis study, we investigated
whether the beneficial effect of an exercise intervention in
patients with mild AD was driven by the patients’ APOE
genotype.
We found that patients who carried the APOE ε4 allele
benefitted more from the exercise intervention than
noncarriers on cognitive, neuropsychiatric, and physical
measures. These findings are in line with the results from
epidemiological studies showing that exercise improved
cognitive and physical performance especially in carriers
of the APOE ε4 allele [13,16].
We found that patients who were carriers of the APOE ε4
allele in the exercise group maintained their performance in
the SDMT test, whereas the carriers of the APOE ε4 allele in
the control group deteriorated in performance. The effect of
exercise on SDMT seen in this study is in line with the
studies in patients with MCI [28] and in older adults [27]
where executive function and performance on SDMT was
improved by exercise. Furthermore, carriers of the APOE
ε4 allele who exercise experienced an improvement in
neuropsychiatric symptoms compared to a worsening in
the control APOE ε4 carrier group. By contrast, we could
m
ea
n
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*
Fig. 1. Mean scores in outcome intention-to-treat analysis. All participants analyzed with independent t-test, respectably of ApoE e4 carrier status and random-
ization group. B: baseline, F: 16-week follow-up, *P , .05, ***P , .001, displayed as mean score in groups with SD.
C.S. Jensen et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 5 (2019) 99-106 103not detect an effect of the exercise intervention on neuropsy-
chiatric symptoms in the noncarrier group.
Carriers of the APOE ε4 allele who exercised improved
their physical performance measured by walking speed
compared both to noncarriers who exercised and to carriers
in the control group. By contrast, we found that the noncar-
riers improved their cardiovascular fitness measured by esti-
mated VO2max but this improvement was not reflected on
their performance on the walking tests. All the participants
in the intervention group had exercised on a stationary
bike and most of them preferred this way of trainingendurance. Some participants did not perform treadmill
walking exercises because they felt unsafe on the treadmill,
and other than the treadmill-workout walking exercises were
not part of the exercise intervention. Sitting on a test bike,
where the movement is very simple and controlled, and
where the assessor ensures that the cadence is kept, is prob-
ably less demanding than walking. Walking requires among
other trunk stability, balance, and coordination. This will
have an impact on the variation of spatiotemporal gait pa-
rameters, which has been shown to be greater in people
with cognitive impairment [39].
C.S. Jensen et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 5 (2019) 99-106104In our previous work [22], we discovered that the highest
effect on cognitive and physical end points was present in
the subgroup of patients who exercised at the highest inten-
sity and with most adhesion to the exercise program, termed
the “high-exercise” group. In the current analysis, we did not
find an additional effect of high exercise after segregating by
APOE ε4 carrier status (data not shown). This could indicate
that the effect exercise on cognitive and physical measures
of carrying the APOE ε4 allele is equivalent to the effect
of a higher intensity exercise regime.
There are several theories regarding why the APOE ε4
allele evolved in humans, and why this allele has been
preserved during evolution up to modern times. Some have
suggested that the APOE ε4 allele evolved in response to
shifts in diet, response to a highly infectious environment,
and need of increased absorption and reuptake of vitamin
D [40,41], cases where the APOE ε4 allele could be
beneficial. The detrimental effects of the APOE ε4 allele,
namely increased risk of atherosclerosis, stroke, and AD,
were counteracted by the higher physical activity of the
hunter-gatherers [42]. In modern societies, where high levels
of physical activity are no longer required, this balance is
skewed toward the adverse effects of the APOE ε4 allele.
This highly speculative hypothesis would fit with the
observation in the present study that physical exercise
counteracts AD-related symptoms to a higher extent in
APOE ε4 carriers than in noncarriers.
The mechanism for our observed APOE-mediated bene-
ficial effect of exercise is unclear. It is not known whether
physical exercise exerts its positive effect through
disease-modifying or symptomatic mechanisms. The
APOE genotypeinfluences several pathways related to
AD, such as vascular damage, A-beta accumulation,
cholesterol transport, and neuroinflammation [4]. In a small
subsample of the ADEX patients, we could not detect an ef-
fect of exercise on CSF levels of biomarkers of AD pathol-
ogy [43] or synaptic function [44], regardless of the
patients’ APOE genotype, and although this could be due
to the small sample size, effects on other downstream path-
ways could be involved, such as positive effects on cerebral
vasculature, improved cholesterol transport, or decreased
neuroinflammation.
A limitation of this study is its exploratory nature because
the ADEX study was not designed to elucidate the effects of
the APOE genotype on an exercise intervention. However,
this study is a large study of 200 patients from a genetically
homogeneous population. All exercise sessions were super-
vised by qualified physical therapists; the exercise intensity
was high as was the adherence to the exercise program. In
our sample, 70% of the patients were carriers of the APOE
ε4 allele; this is slightly higher than the background popula-
tion of patients with AD with approximately 60% being car-
riers of one or two alleles of the APOE ε4 allele in northern
Europe [45]. We have no simple explanation for this differ-
ence other than a possible random selection bias. This imbal-
ance could influence our results because of the smallernumber of subjects not carrying the APOE4 allele giving
rise to a statistical type I error thus potentially not detecting
significant changes thatmight happen in the noncarrier group.
Even if a nonpharmacological intervention such as exer-
cise does not alter the known pathological pathways in AD,
it can still be relevant for delaying disease progression by
either purely symptomatic effects or by affecting some of
the downstream biological processes. If exercise interven-
tions could delay progression of AD and nursing home
placement, this would be of benefit for patients and care-
givers but also for society.
In conclusion, this exploratory study establishes a
possible connection between the beneficial effects of exer-
cise in AD and the patients’ APOE genotype. These findings
need to be replicated in larger studies specifically designed
to investigate a potential causality. If replicated, these find-
ings will contribute to a targeted and more personalized
treatment approach in AD and give new hope for approxi-
mately 14% of the population with an increased genetic
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1. Systematic review: Review of the literature shows
self-reported physical activity is associated with
better cognitive and physical performance in healthy
elderly who carry the APOE ε4 allele.
2. Interpretation: In a post hoc analysis of a large multi-
center study, we find that patients with Alzheimer’s
disease who carry the APOE ε4 allele benefit more
from an exercise intervention on cognitive, neuro-
psychiatric, and physical measures compared to
patients with Alzheimer’s disease who do not carry
the APOE ε4 allele.
3. Future directions: These results need to be validated
in larger studies. If positive, this knowledge could
greatly impact the clinical management of Alz-
heimer’s disease.
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